COR2ED The Heart of Medical Education
Our COR2ED channel brings together world-renowned medical experts to discuss and provide clear guidance on the latest scientific and clinical insights in various therapeutic areas, including oncology, cardiology, hemostasis, rare diseases, hemato-oncology, and endocrinology. At COR2ED, we are committed to providing balanced and evidence-based independent medical education to support healthcare ...
read more ↘
read more ↘
Video Player is loading.
10 seconds
Playback speed
The Evolving Role of Liquid Biopsy in HR+/HER2- mBC
The evolving role of liquid biopsy in HR+/HER2- metastatic breast cancer
In this insightful video, experts Prof. Frédérique Penault-Llorca and Dr Aditya Bardia explore the evolving landscape of biomarker testing in HR+/HER2- metastatic breast cancer. They discuss when and how to effectively utilise liquid and tumour biopsies, the importance of including all relevant biomarkers in test requests throughout the patient journey, and how these testing results directly impact treatment decisions and patient management. This discussion offers valuable guidance for optimising personalised care in advanced breast cancer.
Key clinical takeaways:
- Liquid biopsies offer a less invasive alternative to traditional tissue biopsies in patients with advanced breast cancer, to examine molecular features
- The role of liquid biopsy should be seen as a complementary testing method to tissue-based assays and the information derived should be reviewed in combination with tissue results
- Liquid biopsy can detect mutations such as ESR1 and PIK3CA that are often associated with resistance to endocrine therapies and targeted treatments
- Multigene NGS testing is recommended by the ESMO and NCCN guidelines to ensure a broad spectrum of genetic alterations can be detected
Download the slides for more information at: https://cor2ed.com/precision-oncology-connect/programmes/liquid-biopsy-metastatic-breast-cancer/
For more information and to download the slides, visit: https://cor2ed.com/obstetrics-gynecology-connect/programmes/treatment-options-advanced-endometrial-cancer/
Follow us on social media:
X
LinkedIn
This content is intended for healthcare professionals only. The medical expert in this video is expressing their own views and not those of COR2ED, supporters or their institution. This video is supported by an Independent Educational Grant from Thermo Fisher Scientific
This video is developed by cor2ed.com
Published on January 2025
Subscribe to this channel to stay up to date with new Independent Medical Education programmes as they’re released.
In this insightful video, experts Prof. Frédérique Penault-Llorca and Dr Aditya Bardia explore the evolving landscape of biomarker testing in HR+/HER2- metastatic breast cancer. They discuss when and how to effectively utilise liquid and tumour biopsies, the importance of including all relevant biomarkers in test requests throughout the patient journey, and how these testing results directly impact treatment decisions and patient management. This discussion offers valuable guidance for optimising personalised care in advanced breast cancer.
Key clinical takeaways:
- Liquid biopsies offer a less invasive alternative to traditional tissue biopsies in patients with advanced breast cancer, to examine molecular features
- The role of liquid biopsy should be seen as a complementary testing method to tissue-based assays and the information derived should be reviewed in combination with tissue results
- Liquid biopsy can detect mutations such as ESR1 and PIK3CA that are often associated with resistance to endocrine therapies and targeted treatments
- Multigene NGS testing is recommended by the ESMO and NCCN guidelines to ensure a broad spectrum of genetic alterations can be detected
Download the slides for more information at: https://cor2ed.com/precision-oncology-connect/programmes/liquid-biopsy-metastatic-breast-cancer/
For more information and to download the slides, visit: https://cor2ed.com/obstetrics-gynecology-connect/programmes/treatment-options-advanced-endometrial-cancer/
Follow us on social media:
X
This content is intended for healthcare professionals only. The medical expert in this video is expressing their own views and not those of COR2ED, supporters or their institution. This video is supported by an Independent Educational Grant from Thermo Fisher Scientific
This video is developed by cor2ed.com
Published on January 2025
Subscribe to this channel to stay up to date with new Independent Medical Education programmes as they’re released.
Comments 0
Login to view comments.
Click here to Login
